Sucampo Pharmaceuticals, Inc. (SCMP) Shares Sold by Alliancebernstein L.P.
Alliancebernstein L.P. decreased its stake in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 90.3% during the first quarter, Holdings Channel reports. The fund owned 29,362 shares of the biopharmaceutical company’s stock after selling 273,390 shares during the period. Alliancebernstein L.P.’s holdings in Sucampo Pharmaceuticals were worth $323,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in SCMP. Capital Fund Management S.A. bought a new position in Sucampo Pharmaceuticals during the first quarter valued at approximately $418,000. Algert Global LLC boosted its position in Sucampo Pharmaceuticals by 18.5% in the first quarter. Algert Global LLC now owns 205,529 shares of the biopharmaceutical company’s stock valued at $2,261,000 after buying an additional 32,072 shares during the last quarter. LSV Asset Management boosted its position in Sucampo Pharmaceuticals by 11.4% in the first quarter. LSV Asset Management now owns 2,346,418 shares of the biopharmaceutical company’s stock valued at $25,810,000 after buying an additional 239,200 shares during the last quarter. Eqis Capital Management Inc. boosted its position in Sucampo Pharmaceuticals by 170.6% in the first quarter. Eqis Capital Management Inc. now owns 51,795 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 32,655 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its position in Sucampo Pharmaceuticals by 900.8% in the first quarter. Great West Life Assurance Co. Can now owns 35,778 shares of the biopharmaceutical company’s stock valued at $392,000 after buying an additional 32,203 shares during the last quarter. 58.60% of the stock is currently owned by hedge funds and other institutional investors.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at 10.35 on Monday. Sucampo Pharmaceuticals, Inc. has a one year low of $9.30 and a one year high of $17.55. The firm’s market capitalization is $479.46 million. The firm has a 50 day moving average of $10.71 and a 200 day moving average of $10.68.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The business had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. During the same period in the prior year, the business earned $0.24 EPS. Sucampo Pharmaceuticals’s revenue for the quarter was up 15.3% compared to the same quarter last year. Equities analysts forecast that Sucampo Pharmaceuticals, Inc. will post $1.02 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/14/sucampo-pharmaceuticals-inc-scmp-shares-sold-by-alliancebernstein-l-p.html.
Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 4th. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Maxim Group reissued a “buy” rating and set a $23.00 target price (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday, August 8th. BidaskClub cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Roth Capital set a $30.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $17.63.
In other Sucampo Pharmaceuticals news, insider Jones W. Bryan bought 4,700 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was acquired at an average cost of $10.60 per share, with a total value of $49,820.00. Following the purchase, the insider now owns 4,700 shares in the company, valued at $49,820. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.13% of the stock is currently owned by corporate insiders.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.